XML 40 R27.htm IDEA: XBRL DOCUMENT
v3.24.3

SHAREHOLDERS' EQUITY (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2024
Share-based Payment Arrangement [Abstract] |
Schedule of employee options activity |
|  | Number |  |  | Weighted average exercise price |  |  | Weighted average remaining contractual life (years) |  |  | Aggregate intrinsic value (in thousands) |
Options outstanding as of December 31, 2023 |  |  | 4,723 |  |  | $ | 259.73 |  |  |  | 4.39 |  |  | $ | - |
Granted |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Exercised |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Forfeited |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Options outstanding as of September 30, 2024 |  |  | 4,723 |  |  | $ | 259.73 |  |  |  | 3.62 |  |  | $ | - |
Options exercisable as of September 30, 2024 |  |  | 4,723 |  |  | $ | 259.73 |  |  |  | 3.62 |  |  | $ | - |
Schedule of employee RSUs activity |
|  | Number of shares underlying outstanding RSUs |  |  | Weighted- average grant date fair value |
Unvested RSUs as of December 31, 2023 |  |  | 538,885 |  |  | $ | 6.07 |
Granted |  |  | 14,740 |  |  |  | 4.80 |
Vested |  |  | (218,493 | ) |  |  | 6.56 |
Forfeited |  |  | (3,413 | ) |  |  | 6.86 |
Unvested RSUs as of September 30, 2024 |  |  | 331,719 |  |  | $ | 5.68 |
Schedule of options and RSUs outstanding |
|  |  | Weighted average remaining contractual life (years) (1) |  |  | Options outstanding and exercisable as of September 30, 2024 |  |  | Weighted average remaining contractual life (years) (1) |
Range of exercise price |  |  | Options and RSUs outstanding as of September 30, 2024 |  |  |  |  |  |  |
RSUs only |  |  |  | 331,719 |  |  |  | - |  |  |  | - |  |  |  | - |
$37.6 |  |  |  | 1,774 |  |  |  | 4.49 |  |  |  | 1,774 |  |  |  | 4.49 |
$178.5 - $236.3 |  |  |  | 1,845 |  |  |  | 3.59 |  |  |  | 1,845 |  |  |  | 3.59 |
$350 - $367.5 |  |  |  | 887 |  |  |  | 2.65 |  |  |  | 887 |  |  |  | 2.65 |
$1,277.5 - $3,634.8 |  |  |  | 217 |  |  |  | 0.63 |  |  |  | 217 |  |  |  | 0.63 |
|  |  |  | 336,442 |  |  |  | 3.62 |  |  |  | 4,723 |  |  |  | 3.62 |
Schedule of warrants outstanding and exercisable |
Issuance date |  | Warrants outstanding |  |  | Exercise price per warrant |  |  | Warrants outstanding and exercisable |  | Contractual term
|  | (number) |  |  |  |  |  | (number) |  |
December 31, 2015 (1) |  |  | 681 |  |  | $ | 52.50 |  |  |  | 681 |  | See footnote (1)
December 28, 2016 (2) |  |  | 272 |  |  | $ | 52.50 |  |  |  | 272 |  | See footnote (1)
April 5, 2019 (3) |  |  | 58,350 |  |  | $ | 35.98 |  |  |  | 58,350 |  | October 7, 2024
June 12, 2019 (4) |  |  | 59,523 |  |  | $ | 42.00 |  |  |  | 59,523 |  | December 12, 2024
February 10, 2020 (5) |  |  | 4,054 |  |  | $ | 8.75 |  |  |  | 4,054 |  | February 10, 2025
February 10, 2020 (6) |  |  | 15,120 |  |  | $ | 10.94 |  |  |  | 15,120 |  | February 10, 2025
July 6, 2020 (7) |  |  | 64,099 |  |  | $ | 12.32 |  |  |  | 64,099 |  | January 2, 2026
July 6, 2020 (8) |  |  | 42,326 |  |  | $ | 15.95 |  |  |  | 42,326 |  | January 2, 2026
December 8, 2020 (9) |  |  | 83,821 |  |  | $ | 9.38 |  |  |  | 83,821 |  | June 8, 2026
December 8, 2020 (10) |  |  | 15,543 |  |  | $ | 12.55 |  |  |  | 15,543 |  | June 8, 2026
February 26, 2021 (11) |  |  | 780,095 |  |  | $ | 25.20 |  |  |  | 780,095 |  | August 26, 2026
February 26, 2021 (12) |  |  | 93,612 |  |  | $ | 32.05 |  |  |  | 93,612 |  | August 26, 2026
September 29, 2021 (13) |  |  | 1,143,821 |  |  | $ | 14.00 |  |  |  | 1,143,821 |  | March 29, 2027
September 29, 2021 (14) |  |  | 137,257 |  |  | $ | 17.81 |  |  |  | 137,257 |  | September 27, 2026
|  |  | 2,498,574 |  |  |  |  |  |  |  | 2,498,574 |  |
| (1) | Represents warrants for ordinary shares issuable upon an exercise price of $52.50 per share, which were granted on December 31, 2015 to Kreos Capital V (Expert) Fund Limited (“Kreos”) in connection with a loan made by Kreos to the Company and are currently exercisable (in whole or in part) until the earlier of (i) December 30, 2025 or (ii) immediately prior to the consummation of a merger, consolidation, or reorganization of the Company with or into, or the sale or license of all or substantially all the assets or shares of the Company to, any other entity or person, other than a wholly owned subsidiary of the Company, excluding any transaction in which the Company’s shareholders prior to the transaction will hold more than 50% of the voting and economic rights of the surviving entity after the transaction. None of these warrants had been exercised as of September 30, 2024.
| (2) | Represents common warrants that were issued as part of the $8.0 million drawdown under the Loan Agreement which occurred on December 28, 2016. See footnote 1 for exercisability terms.
| (3) | Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s registered direct offering of ordinary shares in April 2019.
| (4) | Represents warrants that were issued to certain institutional investors in a warrant exercise agreement in June 2019.
| (5) | Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s best efforts offering of ordinary shares in February 2020. As of September 30, 2024, 534,300 warrants were exercised for a total consideration of $4,675,125. During the nine months ended September 30, 2024, no warrants were exercised.
| (6) | Represents warrants that were issued to the placement agent as compensation for its role in the Company’s February 2020 best efforts offering. As of September 30, 2024, 32,880 warrants were exercised for a total consideration of $359,625. During the nine months ended September 30, 2024, no warrants were exercised.
| (7) | Represents warrants that were issued to certain institutional purchasers in a private placement in our registered direct offering of ordinary shares in July 2020. As of September 30, 2024, 288,634 warrants were exercised for a total consideration of $3,556,976. During the nine months that ended September 30, 2024, no warrants were exercised.
| (8) | Represents warrants that were issued to the placement agent as compensation for his role in the Company’s July 2020 registered direct offering.
| (9) | Represents warrants that were issued to certain institutional purchasers in a private placement in our private placement offering of ordinary shares in December 2020. As of September 30, 2024, 514,010 warrants were exercised for a total consideration of $4,821,416. During the nine months that ended September 30, 2024, no warrants were exercised.
| (10) | Represents warrants that were issued to the placement agent as compensation for its role in the Company’s December 2020 private placement. As of September 30, 2024, 32,283 warrants were exercised for a total consideration of $405,003. During the nine months that ended September 30, 2024, no warrants were exercised.
| (11) | Represents warrants that were issued to certain institutional purchasers in a private placement in our private placement offering of ordinary shares in February 2021.
| (12) | Represents warrants that were issued to the placement agent as compensation for its role in the Company’s February 2021 private placement.
| (13) | Represents warrants that were issued to certain institutional purchasers in a private placement in our registered direct offering of ordinary shares in September 2021.
| (14) | Represents warrants that were issued to the placement agent as compensation for its role in the Company’s September 2021 registered direct offering.
Schedule of non-cash share-based compensation expense |
|  | Nine Months Ended September 30, |
|  | 2024 |  |  | 2023 |
Cost of revenues |  | $ | 12 |  |  | $ | 5 |
Research and development, net |  |  | 130 |  |  |  | 112 |
Sales and marketing |  |  | 309 |  |  |  | 270 |
General and administrative |  |  | 596 |  |  |  | 568 |
Total |  | $ | 1,047 |  |  | $ | 955 |

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock options and stock appreciation rights that were outstanding at the beginning and end of the year, exercisable at the end of the year, and the number of stock options and stock appreciation rights that were granted, exercised or converted, forfeited, and expired during the year. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year. + References No definition available. + Details
Name: | us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1 + Details
Name: | us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration